A phase 2 and pharmacological study of sapanisertib in patients with relapsed and/or refractory acute lymphoblastic leukemia,Cancer Medicine

当前位置： X-MOL 学术 › Cancer Med. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

A phase 2 and pharmacological study of sapanisertib in patients with relapsed and/or refractory acute lymphoblastic leukemia
Cancer Medicine ( IF 2.9 ) Pub Date : 2023-11-13 , DOI: 10.1002/cam4.6701
Aref Al-Kali ₁ , Ibrahim Aldoss ₂ , Pamela J Atherton ₁ , Carrie A Strand ₃ , Bijal Shah ₄ , Jonathan Webster ₅ , Bhavana Bhatnagar ₆ , Karen S Flatten ₇ , Kevin L Peterson ₇ , Paula A Schneider ₇ , Sarah A Buhrow ₇ , Jianping Kong ₇ , Joel M Reid ₇ , Alex A Adjei ₈ , Scott H Kaufmann _{1,

7}

Affiliation

Despite recent approval of several new agents, relapsed acute lymphoblastic leukemia (ALL) remains challenging to treat. Sapanisertib (MLN0128/TAK-228) is an oral TORC1/2 inhibitor that exhibited preclinical activity against ALL.

中文翻译：

sapanisertib 在复发和/或难治性急性淋巴细胞白血病患者中的 2 期和药理研究

尽管最近批准了几种新药，但复发性急性淋巴细胞白血病（ALL）仍然难以治疗。Sapanisertib （MLN0128/TAK-228）是一种口服 TORC1/2 抑制剂，对 ALL 表现出临床前活性。

更新日期：2023-11-13

点击分享查看原文

点击收藏

公开下载

阅读更多本刊新发论文本刊介绍/投稿指南